Surrozen, Inc (SRZN): Price and Financial Metrics


Surrozen, Inc (SRZN): $2.77

0.22 (+8.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRZN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SRZN Stock Price Chart Interactive Chart >

Price chart for SRZN

SRZN Price/Volume Stats

Current price $2.77 52-week high $14.00
Prev. close $2.55 52-week low $1.98
Day low $2.48 Volume 2,600
Day high $2.77 Avg. volume 70,479
50-day MA $2.85 Dividend yield N/A
200-day MA $5.55 Market Cap 97.30M

Surrozen, Inc (SRZN) Company Bio


Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.


SRZN Latest News Stream


Event/Time News Detail
Loading, please wait...

SRZN Latest Social Stream


Loading social stream, please wait...

View Full SRZN Social Stream

Latest SRZN News From Around the Web

Below are the latest news stories about Surrozen Inc that investors may wish to consider to help them evaluate SRZN as an investment opportunity.

Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share

NORTH LIBERTY, Iowa, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the quarter and year ended December 31, 2021. Three months ended December 31, 2021: Net Income of $20.3 million and Basic Earnings per Share of $0.26, Operating Revenue of $148.1 million,Operating Income of $26.5 million, an 11.5% increase over 2020,Operating Ratio of 82.1% and 79.2% Non-GAAP Adjusted Operating Ratio(1),Cash balance of $157.7 million and a Debt-Free

Yahoo | January 20, 2022

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and compelling preclinical data highlighting the potential for lacrimal gland and lung programs SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway

Yahoo | January 10, 2022

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen to provide a business update including discussion of pipeline advancementsSOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, will present virtually on January 13, 2022 at 9 a.m. ET, at the 40th J.P. Morgan Healthcare Conference. A live audio webcast of the presentation will be accessible through

Yahoo | January 5, 2022

Surrozen Reports Third Quarter 2021 Financial Results

Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the third quarter ended September 30, 2021 and

Yahoo | November 15, 2021

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website

Yahoo | November 15, 2021

Read More 'SRZN' Stories Here

SRZN Price Returns

1-mo 0.73%
3-mo -3.82%
6-mo -69.46%
1-year -71.94%
3-year N/A
5-year N/A
YTD -56.99%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6516 seconds.